Saturday 17 October 2026
Export ACXP’s income statement to Excel — free account
Acurx Pharmaceuticals, Inc.
ACXP Healthcare Biotechnology
In the quarter to June 2026, EPS grew 72.0% and free cash flow fell 2.36%, each against the same quarter a year earlier.
1.10
0.07
−5.98%
Follow ACXP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(291.07%) | (270.80%) | (160.83%) | (128.11%) | |
| (151.72%) | (137.98%) | (104.54%) | (87.57%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(252.13%) | (151.21%) | (106.92%) | (92.08%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(4.83) | (4.53) | (2.26) | (1.45) | |
Free Cash Flow |
(7.85) | (6.79) | (6.14) | (6.18) | |
| Other line items | |||||
Cash ROIC |
(82.29%) | (52.93%) | (37.77%) | (32.87%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.86 | 0.85 | 0.82 | 0.82 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.83) | (4.53) | (2.26) | (1.45) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates